Your browser doesn't support javascript.
Ecchymotic Plaques Induced by Spikevax: About 2 Cases
Drug Safety ; 45(10):1212-1213, 2022.
Article in English | EMBASE | ID: covidwho-2085640
ABSTRACT

Introduction:

Several post-vaccination adverse events (AEFI) have been reported after anti-COVID 19 vaccine SPIKEVAX administration. By the way, we can mention cutaneous manifestations (1). Objective(s) We report 2 cases of women who presented ecchymotic skin plaques after vaccination with SPIKEVAX notified in the Regional Pharmacovigilance Service of Sfax. Method(s) The assessment of the causal link was made according to the method of the World Health Organization. Result(s) Two women, with no previous medical history, presented ecchymotic skin patches after SPIKEVAX-(Moderna) vaccination. Platelet and D-dimer levels were normal in both cases. But an immunological assessment was not requested. The first woman was 33 years old. She presented 2 days after the first dose of the vaccine generalized ecchymotic plaques which measured 7 cm of diameter and was located on the right flank. These plaques persisted for one month before disappearing. The second woman was 26 years old, she presented 20 days after the second dose of the vaccine, 3 ecchymotic plaques on one thigh followed. Two days later, another plaque was appeared on the other thigh. These lesions were associated with myalgias in the lower limbs and headaches and disappears after 2 months. A probable causal link was established in these patients. Conclusion(s) The ecchymotic plaques in our patients may suggest vascular involvement particularly a vasculitis. Few cases have been reported with anti-COVID 19 vaccination (1).
Keywords

Full text: Available Collection: Databases of international organizations Database: EMBASE Topics: Vaccines Language: English Journal: Drug Safety Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: Databases of international organizations Database: EMBASE Topics: Vaccines Language: English Journal: Drug Safety Year: 2022 Document Type: Article